Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Sacituzumab Tirumotecan”

55 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 55 results

Large-scale testing (Phase 3)Looking for participantsNCT06312137
What this trial is testing

Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Who this might be right for
Non Small Cell Lung Cancer
Merck Sharp & Dohme LLC 780
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07511023
What this trial is testing

Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum

Who this might be right for
Phase 2Sacituzumab TirumotecanRefractory Metastatic+2 more
M.D. Anderson Cancer Center 20
Large-scale testing (Phase 3)Looking for participantsNCT06824467
What this trial is testing

Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Merck Sharp & Dohme LLC 770
Large-scale testing (Phase 3)Looking for participantsNCT06393374
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Who this might be right for
Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC 1,530
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07007780
What this trial is testing

Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC

Who this might be right for
Triple -Negative Breast Cancer
Xijing Hospital 35
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07521670
What this trial is testing

Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)

Who this might be right for
Recurrent Adenoid Cystic CarcinomaAdenoid Cystic Carcinoma MetastaticPapillary Thyroid Carcinoma
National Cancer Centre, Singapore 68
Large-scale testing (Phase 3)Looking for participantsNCT06459180
What this trial is testing

Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Who this might be right for
Cervical Cancer
Merck Sharp & Dohme LLC 686
Not applicableNot Yet RecruitingNCT06993506
What this trial is testing

Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Who this might be right for
HER2-negative Breast CancerRecurrenceMetastasis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 500
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07139470
What this trial is testing

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 59
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07153965
What this trial is testing

Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer (TNBC)PD-L1 Positive
Tianjin Medical University Cancer Institute and Hospital 47
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07054242
What this trial is testing

A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)

Who this might be right for
Neoadjuvant TherapyStage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast Cancer
Yantai Yuhuangding Hospital 52
Large-scale testing (Phase 3)Looking for participantsNCT06312176
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Who this might be right for
Breast Neoplasms
Merck Sharp & Dohme LLC 1,200
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07197008
What this trial is testing

Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis

Who this might be right for
Lung Cancer
Li-kun Chen 50
Testing effectiveness (Phase 2)Looking for participantsNCT06637423
What this trial is testing

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

Who this might be right for
Non-Muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC 32
Large-scale testing (Phase 3)Looking for participantsNCT07419295
What this trial is testing

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

Who this might be right for
Bladder Cancer
Merck Sharp & Dohme LLC 590
Testing effectiveness (Phase 2)Looking for participantsNCT07088211
What this trial is testing

Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC

Who this might be right for
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University 39
Large-scale testing (Phase 3)Looking for participantsNCT06422143
What this trial is testing

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Who this might be right for
Non-small Cell Lung CancerNSCLC
Merck Sharp & Dohme LLC 851
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07438626
What this trial is testing

Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma

Who this might be right for
Phase IISacituzumabTirumotecan+1 more
M.D. Anderson Cancer Center 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07108816
What this trial is testing

A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Resectable Stage II-IIIB NSCLC
Henan Cancer Hospital 52
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07314619
What this trial is testing

Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Recurrent Ovarian Cancer (PROC)
The First Affiliated Hospital of Zhengzhou University 30
Load More Results